The IGF system in patients with inflammatory bowel disease treated with prednisolone or infliximab
Potential role of the stanniocalcin-2 / PAPP-A / IGFBP-4 axis
Hjortebjerg, Rikke; Thomsen, Karen L.; Agnholt, Jørgen; Frystyk, Jan

Published in:
BMC Gastroenterology

DOI:
10.1186/s12876-019-1000-6

Publication date:
2019

Document version
Final published version

Document license
CC BY

Citation for published version (APA):
Hjortebjerg, R., Thomsen, K. L., Agnholt, J., & Frystyk, J. (2019). The IGF system in patients with inflammatory bowel disease treated with prednisolone or infliximab: Potential role of the stanniocalcin-2 / PAPP-A / IGFBP-4 axis. BMC Gastroenterology, 19, [83]. https://doi.org/10.1186/s12876-019-1000-6

Terms of use
This work is brought to you by the University of Southern Denmark through the SDU Research Portal. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:

• You may download this work for personal use only.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to puresupport@bib.sdu.dk
The IGF system in patients with inflammatory bowel disease treated with prednisolone or infliximab: potential role of the stanniocalcin-2 / PAPP-A / IGFBP-4 axis

Rikke Hjortebjerg 1,2*, Karen L. Thomsen 3, Jørgen Agnholt 3 and Jan Frystyk 1,4,5

Abstract

Background: Patients with inflammatory bowel disease (IBD) present with reduced serum insulin-like growth factor I (IGF-I). Anti-inflammatory treatment with prednisolone or infliximab ameliorates symptoms and increases circulating IGF-I, but prednisolone induces catabolism, whereas infliximab may promote protein synthesis. Recently, stanniocalcin-2 (STC2) was discovered as a novel inhibitor of the enzyme pregnancy-associated plasma protein-A (PAPP-A), which modulates IGF-I activity. PAPP-A can cleave IGF binding protein-4 (IGFBP-4), upon which IGF-I is liberated. We hypothesized that prednisolone and infliximab exert different effects on levels of STC2, PAPP-A, and IGFBP-4, thereby explaining the distinct metabolic effects of prednisolone and infliximab.

Methods: Thirty-eight patients with active IBD treated with either prednisolone (n = 17) or infliximab (n = 21) were examined before and after 7 days of treatment. Circulating levels of IGF-I, IGF-II, IGFBP-3, PAPP-A, and STC2 were measured by immunoassays. Intact IGFBP-4 and two IGFBP-4 fragments were determined by a novel immunoassay. Bioactive IGF was assessed by cell-based IGF receptor activation assay. Concentrations of IGFBP-4, PAPP-A, and STC2 on day 0 and 7 were compared to healthy control subjects.

Results: Following seven days of prednisolone treatment, total and bioactive IGF-I were increased (p < 0.001 and p < 0.05, respectively). Upon infliximab treatment, total IGF-I levels were augmented (p < 0.05), yet IGF bioactivity remained unaltered. Intact IGFBP-4 and the two IGFBP-4 fragments generated upon cleavage by PAPP-A were all decreased following treatment with either prednisolone or infliximab (all p < 0.05). PAPP-A levels were only increased by infliximab (p = 0.005), whereas the inhibitor STC2 did not respond to any of the treatments.

Conclusion: IGF-I and IGFBP-4 concentrations were markedly altered in patients with IBD and near-normalized with disease remission following treatment with prednisolone or infliximab. Thus, IGFBP-4 may modulate IGF bioavailability in IBD. The effect of immunosuppression did not appear to extend beyond the regulation of IGF and IGFBP-4, as neither PAPP-A nor STC2 were discernibly affected.

Trial registration: ClinicalTrials.gov: NCT009955123. Date of registration: August 7, 2009 (retrospectively registered).

Keywords: IGF binding protein-4, Inflammatory bowel disease, Infliximab, Prednisolone, Pregnancy-associated plasma protein-a, Stanniocalcin-2
Background
Inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis, are chronic gastrointestinal disorders with unknown etiology [1, 2]. The genetically predisposed IBD patients are characterized by an abnormal intestinal mucosal immune response against the commensal intestinal flora, but the pathogenesis remains poorly understood. Patients present with an ongoing systemic auto-inflammation and various metabolic deteriorations, including submucosal fat deposition, insulin and growth hormone (GH) resistance, hypertension, and dyslipidemia [2, 3]. Current treatment strategies in IBD include corticosteroids and anti-inflammatory biological agents. Prednisolone is a mainstay in the treatment of active IBD, despite numerous deleterious catabolic side-effects such as accelerated protein wasting, decreased protein synthesis, and bone demineralization. In the past two decades, the use of anti-inflammatory biological agents, including antibodies against tumor necrosis factor-α (TNF-α) (infliximab), has become ubiquitous, both as a first-line treatment and when treatment with prednisolone fails to control the inflammation [1].

Patients with active IBD present with reduced serum levels of insulin-like growth factor I (IGF-I) [4, 5], likely secondary to a combination of GH resistance, gastrointestinal dysfunction, and chronic inflammation [3, 6, 7]. IGF-I governs anabolic cellular processes as well as carbohydrate, lipid and protein metabolism [8, 9]. The biological activity of IGF-I is modulated by a family of IGF binding proteins (IGFBPs) as well as a number of IGFBP proteases. Its cognate receptor, the IGF-I receptor (IGF-IR), is ubiquitously expressed in most tissue, including the gastrointestinal tract [6]. Reduction in systemic inflammation following various therapeutic interventions partly reverses GH resistance and often results in near-normalization of circulating IGF-I levels [3, 7]. Interestingly, exposure to prednisolone generally suppresses IGF-I bioactivity within the tissues, while increasing serum IGF-I concentration and ability to activate the IGF-IR in vitro (bioactive IGF) [10]. The paradox appears unrelated to changes in the circulating levels of the IGFBPs, whereas previous studies have suggested that IGF bioactivity may be regulated within the tissues by unknown IGF-I inhibitors [11–13].

Pregnancy-associated plasma protein-A (PAPP-A) is an enzyme with proteolytic activity towards IGFBP-4 [14, 15]. However, IGFBP-4 is only subject to degradation when bound to the IGFs, and as proteolysis renders IGFBP-4 unable to bind its ligand, PAPP-A hereby serves as a stimulator of IGF-I action by liberating IGF [14, 16]. Recently, stanniocalcin-2 (STC2) was identified as a novel inhibitor of PAPP-A [17]. Binding of STC2 to PAPP-A abrogates the enzymatic activity towards IGFBP-4, hereby indirectly decreasing IGF bioactivity (Fig. 1). The effects of the STC2/PAPP-A/IGFBP-4-axis [18] on IGF activity has been linked to a number of pathological conditions, including adipose tissue dysfunction [19, 20], cardiovascular disease [14, 21–24], and cancer [16, 25]. Additionally, PAPP-A is notoriously stimulated by pro-inflammatory cytokines, and thus, we hypothesized that IBD treatments, via their anti-inflammatory effects, may impinge on IGF-I activity via the STC2/PAPP-A/IGFBP-4-axis [26]. Accordingly, the present study aimed to compare the effects of treatment with prednisolone vs. infliximab on the recently acknowledged STC2/PAPP-A/IGFBP-4-axis in patients with active IBD.

Fig. 1 The stanniocalcin-2/PAPP-A/IGFBP-4 axis. Left: PAPP-A cleaves IGFBP-4 into two fragments in the vicinity of the IGF-IR, resulting in liberation of bioactive IGF that can activate its receptor. Right: stanniocalcin-2 inhibits PAPP-A degradation of IGFBP-4, resulting in decreased levels of bioactive IGF and consequently reduced IGF signaling. IGF, insulin-like growth factor; IGF-IR, IGF-I receptor; IGFBP, IGF binding protein; PAPP-A, pregnancy-associated plasma protein-A; STC2, Stanniocalcin-2.

Hjortebjerg et al. BMC Gastroenterology (2019) 19:83 Page 2 of 11
Methods

Patients and study design

Details of the study participants and procedures have previously been described [27]. A total of 38 consecutive patients with active IBD were enrolled, of which 20 patients presented with ulcerative colitis and 18 with Crohn’s disease. The patients had been diagnosed according to the standard clinical, biochemical, endoscopic, and histopathological criteria. Inclusion criteria were age above 18 years and moderate-to-severe active ulcerative colitis or Crohn’s disease that required systemic anti-inflammatory treatment with prednisolone or infliximab.

Thus, all patients exhibited clinically active, inflammatory disease on the basis of standard criteria, including elevated C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), orosomucoid, and fecal calprotectin, and disease activity was furthermore scored according to the Harvey Bradshaw Index (HBI) [28] in patients with Crohn’s disease and the Simple Clinical Colitis Activity Index (SCCAI) [29] in patients with ulcerative colitis. All patients were bio-naïve, but had previously been treated with azathioprine (n = 8), 5-aminosalicylic acid (n = 13), both azathioprine and 5-aminosalicylic acid (n = 2) or budesonide (n = 2). Patients treated with budesonide were not assigned to the prednisolone treatment group. Thirteen patients were newly diagnosed or treatment naïve. Exclusion criteria were the use of either prednisolone or infliximab within 8 weeks prior to enrolment. Furthermore, patients with active infections, malignancies, or other catabolic or chronic inflammatory diseases were excluded. Of the included patients, 17 were treated with prednisolone (13 ulcerative colitis and 4 Crohn’s disease patients), and 21 were treated with infliximab (7 ulcerative colitis and 14 Crohn’s disease patients). The department’s gastroenterologists made the treatment decision according to clinical criteria and before informed consent was obtained from the participant. Intravenous treatment was either with methylprednisolone (40 mg twice daily) (Solu-Medrol, Pfizer, NY, USA) or infliximab (5 mg/kg body weight, one dose) (Remicade; Janssen Biologics B.V., Leiden, Netherlands). Patients receiving infliximab treatment had previously experienced steroid resistance or had severe adverse effects in response to steroid treatment. The two treatment groups were balanced with regard to age, sex, height, and weight. All investigations were performed after an overnight fast. Blood samples were collected from all patients at baseline (day 0) and on day 7 and stored at – 80 °C until analysis.

To specifically characterize the STC2/PAPP-A/IGFBP-4-axis in IBD patients, protein measurements on day 0 and day 7 were compared to healthy control subjects. Control EDTA-plasma for IGFBP-4 and STC2 measurements was collected from 50 randomly selected Danish registered blood donors at Aarhus University Hospital (25 women and 25 men, age range 18–50 years). Control serum for PAPP-A measurements was collected from 150 adults (75 women and 75 men, age 44 ± 15 years) [30]. All donors were healthy and received no medication.

The study was approved by The Local Ethics Committee (Journal no. 20060197) and registered at ClinicalTrials.gov (NCT00955123). Written informed consent was obtained from all participants, and the study conformed to the Declaration of Helsinki.

Laboratory measurements

CRP, ESR, orosomucoid, and creatinine were assayed using routine laboratory methods. Estimated glomerular filtration rate (eGFR) was calculated using the MDRD formula [31]. Cortisol and fecal calprotectin were measured by specific ELISAs (DRG Diagnostics, Marburg, Germany and Bühlmann Laboratories, Schönenbuch, Switzerland, respectively), and TNF-α and IL-6 by highly sensitive immunoassays (RnD Systems, Minneapolis, MN, USA).

Total serum IGF-I was assayed after acid-ethanol extraction using a validated in-house sandwich assay as previously described [32] with minor modifications: the secondary detection antibody was replaced by a biotinylated IGF-I antibody (Cat# I-8773, Sigma-Aldrich, St. Louis, MO, USA). Serum IGF-II concentrations were measured by a validated in-house, time-resolved immunofluorometric assay (TR-IFMA) [33]. IGFBP-3 was determined using the IDS-ISYS Multi-Discipline Automated Analyzer (Immunodiagnostic Systems, Copenhagen, Denmark), as previously published [22].

The ability of serum IGFs to activate the IGF-IR in vitro (bioactive IGF) was determined by an in-house kinase receptor activation assay (KIRA) as originally described [34] with slight modifications. The assay measures the ability of IGF to phosphorylate the IGF-IR in an in vitro-based model employing IGF-IR gene-transfected human embryonic renal cells. In brief, transfected cells were stimulated with diluted serum for 15 min at 37 °C. A serial dilution of rhIGF-I (WHO 02/254) served as calibrator. Following cell lysis, the concentration of phosphorylated IGF-I receptor was determined in the crude cell lysates using a phospho-IGF-IR ELISA (Cat# DYC 1770E, RnD Systems, Abingdon, UK). The KIRA assay signal primarily reflects binding of IGF-I to the IGF-IR, but also binding of IGF-II and pro-IGF-II (cross-reactivity 12 and 2%, respectively). The cross-reactivity of pro-insulin and insulin is negligible (< 1%). Hence, the assay signal is referred to as IGF bioactivity. The KIRA assay has a detection limit < 0.08 μg/L and intra- and inter-assay CVs of 12 and 20%, respectively.
EDTA-plasma levels of intact IGFBP-4 and the two PAPP-A generated fragments, C-terminal (CT)-IGFBP-4 and N-terminal (NT)-IGFBP-4, were measured in duplicate by in-house TR-IFMAs using monoclonal antibodies (mAb) and recombinant human (rh) calibrator, generously provided by HyTest Ltd. (Turku, Finland). The assays were performed as recently described [14, 21–23]. In each fragment assay, one of the antibodies specifically recognized the proteolytic neoepitope generated upon cleavage by PAPP-A. Detection limits were 0.5 μg/L for IGFBP-4, 0.4 μg/L for CT-IGFBP-4 and 0.9 μg/L for NT-IGFBP-4. Intra- and inter-assay CVs were < 10 and < 15%, respectively.

PAPP-A and STC2 levels were determined by commercial sandwich ELISAs (PAPP-A; Cat# AL-101 and STC2; Cat# AL-143) from AnshLabs (Webster, TX, USA). Assay procedures were as described by the manufacturer, and both assays behaved linearly within the analytical range.

Statistics
Baseline data have previously been described and analyzed [27]. The assumption of normality was checked using quantile plots, and non-normally distributed variables were transformed using the natural logarithm prior to statistical analyses. Unpaired continuous observations were analyzed at baseline using Student’s t-test, and paired observations on day 0 and day 7 were analyzed using paired t-test. Variables that remained non-normally distributed upon transformation were analyzed using the nonparametric Wilcoxon signed-ranks test or Mann Whitney U-statistics as appropriate. Categorical variables were compared using χ²-test. Differences in protein concentrations between IBD patients and controls were assessed by unpaired t-test. Correlations were examined using Pearson’s correlation analysis. To investigate the overall change from day 0 to day 7 in IGFBP system parameters and inflammatory and metabolic markers, we calculated delta values in each subject. Correlations between delta values were investigated using Pearson or Spearman correlation coefficients as appropriate. The proteins investigated in the present study have previously shown to provide ample statistical power in cohorts of 9–24 subjects [10, 35, 36], supporting that differences in proteins levels would be detectable in a cohort of 38 patients. Data are reported as means ± SD for normally distributed variables and medians with interquartile range for non-normally distributed variables. Level of significance was p < 0.05. Statistical analyses were performed using STATA 13 (StataCorp, College Station, TX, USA).

Results
Baseline characteristics and disease activity
Measurement details of healthy subjects and IBD patients before and after treatment are summarized in Table 1. At baseline, disease scores, CRP, ESR, orosomucoid, fecal calprotectin, cortisol, TNF-α and IL-6 were higher compared with levels in healthy subjects (reference levels not shown), but similar in the two treatment groups. The eGFR was slightly higher in the infliximab group. Irrespective of anti-inflammatory treatment, patient SCCAI and HBI disease scores as well as CRP, ESR, orosomucoid, and fecal calprotectin improved during the course. Both treatments resulted in reduced IL-6 levels, whereas infliximab triggered a possibly compensatory increment in TNF-α levels. These data have previously been published [27].

The IGF system in patients with IBD treated with prednisolone or infliximab
Paired individual levels of IGF system proteins are shown in Fig. 2. At baseline, IGF-I levels were higher in the infliximab group, whereas IGF-II, IGF bioactivity, and IGFBP-3 levels were similar in the two treatment groups (Table 1). Following seven days of prednisolone treatment, both total IGF-I concentration and bioactive IGF, as measured by in vitro IGF-IR activation, were significantly increased (p < 0.001 and p = 0.048, respectively). In contrast, concentrations of IGF-II and IGFBP-3 remained unchanged. When looking at the individual changes, six patients demonstrated numerically lower levels of bioactive IGF after prednisolone treatment, whereas 11 patients showed numerically higher levels following prednisolone. By contrast, the concentration of IGF-I was only reduced in two patients. Upon infliximab treatment, levels of IGF-I, IGF-II, and IGFBP-3 were slightly increased (p = 0.025, p = 0.049, and p = 0.035, respectively), whereas IGF bioactivity remained unaltered.

The STC2/PAPP-A/IGFBP-4-axis
Patients with IBD vs. healthy control subjects
Neither on day 0 nor day 7 did intact IGFBP-4 levels differ from those of healthy controls. However, CT- and NT-IGFBP-4 levels were significantly higher at baseline in both the prednisolone and infliximab group (all p < 0.001), and both protein concentrations were normalized upon treatment. To assess the degree of IGFBP-4 degradation, we calculated ratios between each fragment and intact IGFBP-4. As compared to healthy controls, the CT-IGFBP-4/IGFBP-4 and NT-IGFBP-4/IGFBP-4 ratios were significantly higher on day 0 and 7 in both the prednisolone and infliximab group (all p < 0.005), suggesting an increased proteolytic degradation that was not remedied by treatment. In the prednisolone group, PAPP-A levels were above normal both before and after therapy (all p < 0.001). STC2 levels were similar in IBD patients and controls.

Patients with IBD treated with prednisolone or infliximab
Prior to treatment, IGFBP-4, IGFBP-4 fragments, and STC2 concentrations were of similar magnitude in the
Table 1 Baseline characteristics and protein levels at baseline and 7 days after treatment with prednisolone or infliximab. Data are mean ± SD or median (25th percentile; 75th percentile)

| Characteristics                           | Healthy subjects | Prednisolone (n = 17) | Infliximab (n = 21) | P Group, day 0 |
|-------------------------------------------|------------------|-----------------------|---------------------|---------------|
| Baseline characteristics                  |                  | Day 0                 | Day 7               | Day 0         | Day 7         |
| Ulcerative colitis/ Crohn’s disease (n)   | 13/4             | 7/14                  | 7/14                | 0.008         |
| Age (years)                               | 34.4 ± 8.9       | 30.5 ± 11.0           | 0.243               |
| Male/female (n)                           | 10/7             | 10/11                 | 0.492               |
| BMI (kg/m2)                               | 23.3 ± 4.5       | 25.1 ± 5.8            | 0.306               |
| SCCAI (mm/h)                              | 9 (7;10)         | 2 (1.2)**             | 8 (5.9)* 2 (1.4)*   | 0.537         |
| HBI (μg/L)                                | 8 (5;13)         | 4 (1.6)*              | 5.5 (3.8) 2 (1.3)** | 0.243         |
| CRP (mg/L)                                | 12.8 (3.6;21.5)  | 7.2 (3.5;21.2)**      | 7.2 (3.5;21.2) 2.7 (1.4;7.9)* | 0.587         |
| ESR (mm/h)                                | 14 (7.27)        | 6 (5;10)**            | 13.5 (8;19.5) 11 (7;16)* | 0.647         |
| Orosomucoid (g/L)                         | 1.4 ± 0.4        | 1.2 ± 0.5*            | 1.3 ± 0.4 1.0 ± 0.3** | 0.383         |
| Calprotectin (mg/kg)                      | 2072 ± 1254      | 1100 ± 1124**         | 1569 ± 1099 810 ± 777** | 0.311         |
| Cortisol (μg/L)                           | 129 (107;255)    | 435 (27;941)          | 125 (104;154) 129 (110;141) | 0.364         |
| Insulin (pmol/L)                          | 44 ± 38          | 42 ± 17               | 45 ± 25 49 ± 26     | 0.865         |
| TNF-α (ng/L)                              | 1.5 ± 1.0        | 1.1 ± 1.9             | 1.1 ± 0.9 11.5 ± 60** | 0.173         |
| IL-6 (ng/L)                               | 2.9 ± 2.6        | 1.6 ± 1.5*            | 2.8 ± 1.6 1.7 ± 1.7* | 0.973         |
| IGF-I (μg/L)                              | 128 ± 36         | 185 ± 67**            | 159 ± 33 178 ± 50*  | 0.009         |
| IGF-II (μg/L)                             | 502 ± 61         | 502 ± 60              | 495 ± 71 518 ± 75*  | 0.746         |
| IGF bioactivity (μg/L)                    | 1.08 ± 0.36      | 1.34 ± 0.52*          | 1.23 ± 0.42 1.33 ± 0.45 | 0.260         |
| IGFBP-3 (μg/L)                            | 4120 ± 583       | 4332 ± 771            | 4220 ± 687 4417 ± 687* | 0.638         |
| IGFBP-4 (μg/L)                            | 174 ± 79         | 184 (146;315)         | 132 (111;188)* 183 (152;207) 164 (97;209)* | 0.410         |
| CT-IGFBP-4 (μg/L)                         | 72 ± 18          | 112 ± 33†             | 79 ± 41** 99 ± 35* 78 ± 35** | 0.246         |
| CT-IGFBP-4/IGFBP-4 ratio                  | 0.41 (0.29;0.53) | 0.61 ± 0.27†          | 0.57 ± 0.35† 0.55 ± 0.15† 0.59 ± 0.36† | 0.443         |
| NT-IGFBP-4 (μg/L)                         | 153 ± 41         | 257 ± 111†            | 179 ± 93** 207 ± 76* 170 ± 78** | 0.108         |
| NT-IGFBP-4/IGFBP-4 ratio                  | 0.80 (0.61;0.99) | 1.34 ± 0.57†          | 1.28 ± 0.72† 1.16 ± 0.31† 1.30 ± 0.84† | 0.223         |
| PAPP-A (μg/L)                             | 0.81 ± 0.26      | 1.17 ± 0.66†          | 1.21 ± 0.56† 0.76 ± 0.37 0.87 ± 0.33* | 0.019         |
| STC2 (μg/L)                               | 25.0 (21.2;28.1) | 22.2 ± 5.2            | 21.5 ± 4.8 22.9 ± 5.6 24.3 ± 7.6 | 0.698         |

Categorical variables are indicated as numbers (n) of patients. Comparison of groups on day 0 was performed by Student’s t-test, and comparison of observations on day 0 and day 7 within the same treatment group were performed using paired t-test. CRP, ESR, and cortisol were analyzed using the nonparametric Wilcoxon matched-pairs signed-ranks test or the Mann-Whitney U-statistics as appropriate. Differences in protein concentrations between patients and controls were assessed by unpaired t-test. Categorical variables were compared using \( \chi^2 \)-test. \* \( P < 0.05 \), \** \( P < 0.005 \) when compared to day 0 within the same treatment group. \# \( P < 0.05 \) for differences between IBD patients and controls on day 0 or day 7. BMI body mass index, CRP C-reactive protein, CT C-terminal, eGFR estimated glomerular filtration rate, ESR erythrocyte sedimentation rate, HBI Harvey-Bradshaw Index, IGF insulin-like growth factor, IGFBP IGF binding protein, IL-6 interleukin-6, NT N-terminal, PAPP-A pregnancy-associated plasma protein-A, SCCAI Simple Clinical Colitis Activity Index, STC2 Stanniocalcin-2, TNF-α tumour necrosis factor-α.

two groups, whereas PAPP-A levels were higher in the prednisolone group. Intact IGFBP-4 was reduced upon both prednisolone as well as infliximab treatment \( (p = 0.035 \) and \( p = 0.044 \), respectively), and similar responses were observed for CT-IGFBP-4 and NT-IGFBP-4 \( (p < 0.001) \). Since both intact and fragmented IGFBP-4 decreased in parallel, ratios between intact IGFBP-4 and each fragment were inspected at each time point. Independent of treatment, the CT-IGFBP-4/IGFBP-4 and NT-IGFBP-4/IGFBP-4 ratios remained unaltered during the course, and thus, the relative degradation of IGFBP-4 on day 0 and day 7 appeared to be of similar magnitude. PAPP-A levels remained unaffected by prednisolone but were significantly increased by infliximab \( (p = 0.005) \). The PAPP-A inhibitor STC2 did not respond to any of the treatments.

Associations between IGF system proteins and inflammatory and metabolic parameters

Total IGF-I and IGF bioactivity were not correlated on day 0 \( (r = 0.22, p = 0.19) \), but were strongly associated on day 7 \( (r = 0.72, p < 0.001) \). At baseline, intact IGFBP-4 was negatively correlated with PAPP-A \( (r = -0.31, p < 0.05) \) and positively correlated with CT- and NT-IGFBP-4 \( (r = 0.45, p < 0.005 \) and \( r = 0.48, p < 0.005 \), respectively). In addition, a strong positive correlation was observed...
Fig. 2 (See legend on next page.)
between concentrations of CT- and NT-IGFBP-4 at both time points (day 0: \( r = 0.84, p < 0.001 \), and day 7: \( r = 0.93, p < 0.001 \)). CT- and NT-IGFBP-4 were positively associated with TNF-\( \alpha \) at baseline (\( r = 0.34, p < 0.05 \) and \( r = 0.44, p < 0.01 \), respectively), and negatively associated with eGFR (day 0: \( r = -0.48, p < 0.005 \) and \( r = -0.62, p < 0.001 \), respectively, and day 7: \( r = -0.34, p < 0.05 \) and \( r = -0.43, p < 0.01 \), respectively). IGF system proteins did not correlate with CRP, IL-6 or the functional hepatic nitrogen clearance at either time point.

To investigate the individual change from baseline in IGF system parameters within each subject, we calculated the delta values from day 0 to day 7. We observed a positive association between the delta value of IGF-I and IGF-II, bioactive IGF, IGFBP-3, IGFBP-4, NT-IGFBP-4, CT-IGFBP-4, PAPP-A, and STC2 before and after 7 days of prednisolone or infliximab. Solid lines illustrate patients, in which protein levels were increased following therapy, whereas dashed lines show patients that had lowered protein levels. Red diamonds illustrate mean or median protein level before and after treatment. CT, C-terminal; IGF, insulin-like growth factor; IGFBP, IGF binding protein; NS, not significant; NT, N-terminal; PAPP-A, pregnancy-associated plasma protein-A; STC2, Stanniocalcin-2.

**Discussion**

Prednisolone and infliximab represent two distinct anti-inflammatory treatments of patients with IBD. Both treatments effectively alleviate active disease, albeit acting through different mechanisms and having distinct metabolic effects. Prednisolone induces catabolism, whereas infliximab may promote protein synthesis [27]. Still, both treatments increase serum IGF-I concentrations [3, 5, 7, 37]. We hypothesized that prednisolone and infliximab would have distinct effects on a recently acknowledged regulatory system that controls IGF-I action independently of circulating IGF-1 concentrations; the STC2/ PAPP-A/ IGFBP-4-axis. This axis has been associated with numerous inflammatory states [16, 25], and thus, anti-inflammatory treatment may likely influence on the STC2/PAPP-A/IGFBP-4-axis [26]. To this end we compared the responses of the IGF system in IBD patients treated for 7 days with prednisolone or infliximab, paying specific attention to STC2, PAPP-A, and IGFBP-4. In agreement with the preponderance of evidence from studies in IBD patients, reduction in systemic inflammation following prednisolone or infliximab treatment was associated with an increase in circulating IGF-I levels [3, 5, 7, 37]. Infliximab, but not prednisolone, increased IGF-II and IGFBP-3. However, in contrast to our expectations, prednisolone, but not infliximab, increased bioactive IGF in serum. As a novel finding, both treatments caused significant reductions in intact and fragmented IGFBP-4 levels. These changes occurred independently of STC2 and PAPP-A, which both remained virtually unaffected by either treatment. Thus, the effect of immunosuppression did not appear to extend beyond the regulation of IGF and IGFBP-4. In conjunction, our study implies that the distinct metabolic effects of prednisolone and infliximab may primarily be regulated at the local tissue level rather than through alterations in the circulating IGF system.

Prednisolone is a glucocorticoid receptor agonist, and its anti-inflammatory actions involve inhibition of potent mediators of inflammation such as cytokines, prostaglandins, and leukotrienes. Infliximab is a chimeric monoclonal antibody that neutralizes the activity of circulating TNF-\( \alpha \), which is primarily produced by activated macrophages in response to inflammation. Infliximab also induces immune cell apoptosis through reverse signaling via transmembrane TNF-\( \alpha \), thereby reducing the production of other pro-inflammatory cytokines [38–40]. Prednisolone exhibits significant adverse effects, such as insulin resistance and catabolism, whereas metabolic side effects attributable to infliximab are less common. Interestingly, in our study, prednisolone also increased IGF bioactivity, whereas this increment did not follow infliximab administration. Data on the relationship between total and bioactive IGF in response to immune-modulating therapy are equivocal. A recent study in healthy males treated with prednisolone (37.5 mg daily) for 5 days demonstrated augmented total and bioactive IGF-I levels [10]. In contrast, in asthmatic children treated with low dose prednisolone (5 mg daily) for 1 week, IGF bioactivity was diminished despite unaltered total and free IGF-I [12], and IBD patients on 8–12 weeks prednisolone demonstrated increased total IGF-I, whereas free IGF-I was unchanged in patients with Crohn’s disease and increased in ulcerative colitis [41]. Infliximab treatment of patients with Crohn’s disease has been shown to augment total IGF-I, but to suppress free IGF-I levels [7].
It is reasonable to assume that the effects of prednisolone and infliximab on total IGF-I occur primarily as a result of the attenuated inflammation. Furthermore, IGF-I and pro-inflammatory cytokines are disparately regulated, as inflammation leads amino acids away from muscle accretion and growth toward hepatic acute-phase protein synthesis [42]. TNF-α is reported to decrease hepatic GH receptor synthesis and as a result of this, hepatic IGF-I and IGFBP-3 production, and this readily explains why infliximab increases serum IGF-I [3, 7]. In contrast, exposure to prednisolone affects the IGF system at multiple levels, resulting in blunted mRNA expression, hormone release, receptor abundance, and signal transduction [43], yet endocrine IGF-I remains unaltered or even increased [12, 13]. It is contradictory that prednisolone induces an increase in circulating IGF-I and at the same time exerts catabolic effects on muscle and bone by releasing amino acids into the bloodstream to provide substrate supply for hepatic urea synthesis [27]. The dual outcome suggests that the beneficial anti-inflammatory effect of prednisolone on the IGF axis overcomes its adverse catabolic properties. Thus, upon treatment, IGF-I may still remedy the steroid-induced protein wasting and contribute towards whole-body anabolism. Part of the dual effect could also arise from a relieved blockade of GH secretion induced at the hypothalamic-pituitary level, and putatively, serum IGF-I concentration and action may increase in response to prednisolone-induced insulin resistance, whereas it may disrupt IGF-I signaling at the tissue level. Indeed, it was recently demonstrated that prednisolone results in cellular IGF-I resistance by impeding IGF-IR downstream signaling [10].

There is a strong consensus that IGFBP-4 attenuates IGF bioactivity in most physiological contexts, and thus, prednisolone and infliximab may influence on IGF-I action through the STC2/PAPP-A/IGFBP-4-axis. The idea gains support from studies in murine models, which also have illustrated that the biological function of the axis is not straightforward [36]. Disruption of the PAPP-A gene results in increased abundance of IGFBP-4 that manifests as a 40% growth retardation and an extended lifespan by up to 40% as compared to wild type littermates [20, 44, 45]. Similarly, inactivation of PAPP-A enzymatic activity by transgenic overexpression of STC2 results in a 45% growth deficit [46, 47]. Interestingly, neither of the mouse models show serum IGF-I levels that diverge from those of wild type animals, implying that the axis regulates local IGF bioactivity within the tissues without affecting circulating IGF-I levels [17, 47]. However, in contrast to the expectation, severe growth retardation also accompanies IGFBP-4 deletion, confirming that IGFBP-4 impinge on growth in positive and negative directions and is indeed required for optimal IGF-mediated growth [45, 48, 49].

Our findings following immune-modulating treatment concur with a previous study, in which intact IGFBP-4 and IGFBP-4 fragments were equally suppressed in healthy males treated with prednisolone for 5 days, while PAPP-A remained unaffected. In theory, the decrease in intact IGFBP-4 level could be attributed to an increase in PAPP-A proteolytic activity. However, the proportion of IGFBP-4 fragment as compared to intact IGFBP-4 was of similar magnitude before and after either treatment, and thus, the infliximab induced increment in circulating PAPP-A was not reflected in correspondingly low levels of intact IGFBP-4 and elevated levels of IGFBP-4 fragments. Thus, our data yields no evidence that prednisolone affects circulating PAPP-A proteolytic activity differently than infliximab. Instead, our finding suggests that prednisolone and infliximab affect IGFBP-4 protein transcription or translation either directly or indirectly. The IGFBP-4 reductions may in part be due to compensatory mechanisms, with e.g. IGFBP-4 translation being downregulated in response to the pronounced alterations within the IGF system. Furthermore, it is likely that the diminution in IGFBP-4 may not be directly driven by prednisolone or infliximab, but by the ensuing reduction in inflammation. IGFBP-4 has previously been shown to be upregulated upon TNF-α exposure [50, 51], and it is tenable that increased IGFBP-4 production in response to inflammation affects IGF bioavailability. PAPP-A is also notoriously associated with inflammatory states, and both IL-6 and TNF-α are invariably powerful stimulators [26, 52, 53]. However, despite reduced systemic inflammation, neither patient group experienced a reduction in serum PAPP-A levels upon treatment. The infliximab group presented with increased concentrations. In most patients, anti-TNF-α therapy causes a rebound production of soluble TNF-α to counteracts its effects [38], and thus, it is highly plausible that the slight increase in PAPP-A is driven by increased serum TNF-α concentrations [54, 55].

Interestingly, at baseline, intact IGFBP-4 did not differ from healthy controls, yet IGFBP-4 fragment levels were significantly elevated and as were the ratios. This finding indicates an increased total IGFBP-4 synthesis and subsequently increased fragmentation in untreated IBD patients, causing IGFBP-4 production to appear (erroneously) normal. To fit with this hypothesis, PAPP-A, being the principal if not only IGFBP-4 protease [56], ought to be augmented in patients with IBD, but neither levels of total PAPP-A nor STC2 deviated from healthy controls at baseline. However, in the circulation, other inhibitors than STC2 are present (e.g. eosinophil major basic protein), which renders PAPP-A inactive towards it substrates [56]. Unfortunately, PAPP-A assays do not distinguish between enzymatically active and inactive forms, and we cannot preclude that PAPP-A activity is
affected in untreated IBD patients by other inhibitors [14]. Evidently, much needs to be learned about the regulation and role of IGFBP-4 in inflammatory states.

In the present work, a number of shortcomings should be addressed. Firstly, patients were only studied for 1 week, and measurements were only conducted on day 0 and day 7. A longer follow-up period would have allowed for complete remission, and repeated measurements would have provided a more detailed picture of the disease improvement. Secondly, the shifts in protein levels may not only be an effect of treatment, but rather a reflection of overall amelioration in disease activity. Finally, GH was not measured in this cohort, and only IGF-I was assessed as a marker of GH action. However, GH measurements may have provided additional information.

**Conclusion**

In patients with IBD, IGFBP-4 and its fragments were reduced by prednisolone and infliximab therapy either directly or indirectly in response to the resultant reduction in inflammation. If so, inflammation may be a critical determinant of IGFBP-4 and, to some extent, PAPP-A activity. Thus, the findings add to the growing body of evidence linking the STC2/PAPP-A/IGFBP-4-axis to inflammatory diseases. However, the clinical and pathophysiological importance of this dysregulation, and whether the system partakes in the onset or progression of disease, remains a conundrum and warrants further studies.

**Abbreviations**

BMI: Body mass index; CRP: C-reactive protein; CT: C-terminal; eGFR: Estimated glomerular filtration rate; ESR: Erythrocyte sedimentation rate; GH: Growth hormone; HBI: Harvey-Bradshaw index; IBD: Inflammatory bowel disease; IGF: Insulin-like growth factor; IGFBP: IGF binding protein; IL-6: Interleukin-6; KIRA: Kinase receptor activation assay; NS: Not significant; NT: N-terminal; PAPP-A: Pregnancy-associated plasma protein-A; SCCAI: Simple Clinical Colitis Activity Index; STC2: Stanniocalcin-2; TNF-α: Tumour necrosis factor-α

**Acknowledgements**

The authors thankfully acknowledge the technicians at Medicinal Research Laboratory for technical assistance. We are grateful to HyTest Ltd. for providing calibrators and antibodies for the IGFBP-4 assays.

**Authors’ contributions**

RH, KLT, JA, and JF conceived and designed the study. RH and KLT performed the experiments and acquired the data. Study material was provided by RH and KLT. Data interpretation, statistical analyses, and drafting of manuscript were performed by RH. All authors revised and approved the manuscript. RH had full access to all data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Funding**

The study was financially supported by the Danish Colitis-Crohn Society, the Beckett Foundation, the Novo Nordisk Foundation, the Aarhus University Research Foundation, and the Danish Council for Strategic Research. RH was funded by the Danish Diabetes Academy supported by the Novo Nordisk Foundation.

**Availability of data and materials**

The dataset used and analyzed during the current study is not publicly available due to the General Data Protection Regulation but is available in fully anonymized form from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

The study was approved by The Local Ethics Committee (Journal no. 20060197) and registered at ClinicalTrials.gov (NCT00955123). Written informed consent was obtained from all participants, and the study conformed to the Declaration of Helsinki.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1 Medical Research Laboratory, Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark. 2 The Danish Diabetes Academy, Odense, Denmark. 3 Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark. 4 Department of Clinical Research, Faculty of Health, University of Southern Denmark, Odense, Denmark. 5 Department of Endocrinology, Odense University Hospital, Odense, Denmark.

**Received:** 31 August 2018 **Accepted:** 23 May 2019

**Published online:** 03 June 2019

**References**

1. Cohen BL, Sachar DB. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017;357:j2505i.
2. Michalak A, Mosirinka P, Fichna J. Common links between metabolic syndrome and inflammatory bowel disease: current overview and future perspectives. Pharmacol Rep. 2016;68(4):837–46.
3. Gentilucci UV, Caviglia R, Picardi A, Carotti S, Ribolzi M, Galati G, et al. Infliximab reverses growth hormone resistance associated with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;21(9):1063–71.
4. Katsanos KH, Tatsoulis A, Christodoulou D, Challa A, Katsaraki A, Tsianos EV. Reduced serum insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 levels in adults with inflammatory bowel disease. Growth Hormon IGF Res. 2001;11(6):364–67.
5. Grönbaek H, Thogersen T, Frystyk J, Vlietinck H, Flyvbjerg A, Dahlerup JF. Low free and total insulin-like growth factor I (IGF-I) and IGF binding protein-3 levels in chronic inflammatory bowel disease: partial normalization during prednisolone treatment. Am J Gastroenterol. 2002;97(1):673–8.
6. Zatorski H, Marynowski M, Fichna J. Is insulin-like growth factor 1 (IGF-1) system an attractive target inflammatory bowel diseases? Benefits and limitation of potential therapy. Pharmacol Rep. 2016;68(4):809–15.
7. Eivindson M, Grønbaek H, Skogstrand K, Thorsen P, Frystyk J, Flyvbjerg A, et al. The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn’s disease. Scand J Gastroenterol. 2007;42(4):464–70.
8. Hjortebjerg R, Flyvbjerg A, Frystyk J. Insulin growth factor binding proteins as therapeutic targets in type 2 diabetes. Expert Opin Ther Targets. 2014;18(2):209–24.
9. Hjortebjerg R, Frystyk J. Determination of IGFs and their binding proteins. Best Pract Res Clin Endocrinol Metab. 2014;27(6):771–81.
10. Ramsbøllinger N, Aagaard M, Hjortebjerg R, Voss TS, Möller N, Jorgensen JOL, et al. Effects of prednisolone on serum and tissue fluid IGF-I receptor activation and post-receptor signaling in humans. J Clin Endocrinol Metab. 2017;102(11):4031–40.
11. Untrierman LS, Phillips SL. Glucocorticoid effects on somatotropes and somatotropin inhibitors. J Clin Endocrinol Metab. 1985;55(4):619–25.
12. Frystyk J, Schou AJ, Heuck C, Voth H, Lyngholm M, Flyvbjerg A, et al. Prednisolone reduces the ability of serum to activate the IGF1 receptor in vitro without affecting circulating total or free IGF1. Eur J Endocrinol. 2013;168(1):1–8.
13. Millet JP, Taylor AM, Jones J, Holly JMP, Gaillard RC, Pralong FP, et al. The effects of dexamethasone treatment on immunoreactive and bioactive
insulin-like growth factors (IGFs) and IGF-binding proteins in normal male volunteers. J Endocrinol. 1993;136(3):525–33.

14. Hjortebjerg R, Lindberg S, Hoffmann S, Jensen JS, Oxvig C, Bjerre M, et al. PAPP-A and IGFBP-4 fragment levels in patients with ST-elevation myocardial infarction treated with heparin and PCI. Clin Biochem. 2015;48(4–5):322–8.

15. Conover CA. Key questions and answers about pregnancy-associated plasma protein-a. Trends in Endocrinology & Metabolism. 2012;23(5):242–9.

16. Thomsen J, Hjortebjerg R, Espelund U, Ortoft G, Vestergaard P, Magnusson NE, et al. PAPP-A proteolytic activity enhances IGF bioactivity in acetes from women with ovarian carcinoma. Oncotarget. 2015;6(31):32266–78.

17. Jepsen MR, Klæverup S, Mikkelsen JH, Pedersen JH, Füchtbauer EM, Laursen LS, et al. Stanniocalcin-2 inhibits mammalian growth by proteolytic inhibition of the insulin-like growth factor-Axis. J Biol Chem. 2015;290(6):3430–9.

18. Oxvig C. The role of PAPP-A in the IGF system: location, location, location. J Cell Commun Signal. 2015;3(2):177–87.

19. Gude MF, Hjortebjerg R, Oxvig C, Thyg AA, Magnusson NE, Bjerre M, et al. PAPP-A, IGFBP-4 and IGF-II are secreted from human adipose tissue cultures in a depot-specific manner. Eur J Endocrinol. 2016;175(6):509–19.

20. Conover CA, Harstad SL, Tchkonia T, Kirkland JL. Preferential impact of estrogen on bioactive IGF1 in GH-deficient women. Eur J Endocrinol. 1995;133(2):E149–E55.

21. Hjortebjerg R, Tarnow L, Jorsal A, Parving H-H, Rossing P, Bjerre M, et al. Insulin-like growth factor binding protein-3 as markers of cardiovascular mortality in type 1 diabetes patients with and without nephropathy. J Clin Endocrinol Metab. 2015;100(8):3032–40.

22. Hjortebjerg R, Laugesen E, Høyem P, Oxvig C, Stausbøl-Grøn B, Knudsen ST, et al. The IGF system in patients with type 2 diabetes associations with markers of cardiovascular target organ damage. Eur J Endocrinol. 2017;176(5):521–31.

23. Hjortebjerg R, Lindberg S, Pedersen S, Mogelvang R, Jensen JS, Oxvig C, et al. Insulin-like growth factor binding protein 4 fragments provide incremental prognostic information on cardiovascular events in patients with ST-segment elevation myocardial infarction. J Am Heart Ass. 2017;6(3):1–12. https://www.ahajournals.org/doi/10.1161/JAHA.116.005358.

24. Hoefflich A, David R, Hjortebjerg R. Current IGFBP-related biomarker research in cardiovascular disease – we need more structural and functional information in clinical studies. Front Endocrinol. 2018;9:388.

25. Eivindson M, Gøranbæk H, Flyvbjerg A, Zimmermann-Nielsen E, Dahlérup JF. The insulin-like growth factor (IGF)-system in active ulcerative colitis and Crohn’s disease: relations to disease activity and corticosteroid treatment. Growth Hormon IGF Res. 2007;17(1):33–40.

26. Frost RA, Lang CH. Alteration of somatotropic function by proinflammatory cytokines. J Anim Sci. 2004;82:E-Suppl100–9.

27. Hochberg Z. Mechanisms of steroid impairment of growth. Horm Res. 2002;58(Suppl 1):133–8.

28. Conover CA, Bale LK, Overgaard MT, Johnstone EW, Laursen UH, Füchtbauer EM, et al. Metalloproteinase pregnancy-associated plasma protein-a is a critical growth regulatory factor during fetoplacental development. Development. 2004;131(5):1187–94.

29. Ning Y, Schuller AGP, Conover CA, Pintar JE. Insulin-like growth factor (IGF) binding Protein-4 is both a positive and negative regulator of IGF activity in vivo. Mol Endocrinol. 2008;22(5):1213–25.

30. Chang AC, Hook J, Lernack FT, McDonald MM, Nguyen MA, Hardeman EC, et al. The murine stanniocalcin 2 gene is a negative regulator of postnatal growth. Endocrinology. 2008;149(5):2403–10.

31. Gagliardi AD, Niu YY, Rauh WJ, Wagner GF, DiMattia GE. Human insulin-like growth factor binding protein-4 fragments as markers of cardiovascular mortality in type 1 diabetes patients. Horm Res. 2005;64:322–6.

32. Eder P, Konyalska K, Lykowska-Szuber L, Stawczyk-Eder K, Krela-Kazmierzczak I, Luczak J, et al. An increase in serum tumour necrosis factor-alpha during anti-tumour necrosis factor-alpha therapy for Crohn’s disease – a paradox or a predictive index? Dig Liver Dis. 2014;46(10):1168–71.

33. Ebert EC. Inflammab and the TNF-a system. Am J Pathol. 1995;206(6):G612–G20.

34. Waetzig GH, Rosentiel P, Aart A, Brautigam K, Schafer H, et al. Soluble tumor necrosis factor (TNF) receptor-1 induces apoptosis via reverse TNF signaling and autocrine transforming growth factor-beta1. FASEB J: official publication of the Federation of American Societies for Experimental Biology. 2005;19(1):1–3.

35. Eivindson M, Gøranbæk H, Flyvbjerg A, Frystyk J, Zimmermann-Nielsen E, Dahlérup JF. The insulin-like growth factor (IGF)-system in active ulcerative colitis and Crohn’s disease: relations to disease activity and corticosteroid treatment. Growth Hormon IGF Res. 2007;17(1):33–40.

36. Frost RA, Lang CH. Alteration of somatotropic function by proinflammatory cytokines. J Anim Sci. 2004;82:E-Suppl100–9.

37. Hochberg Z. Mechanisms of steroid impairment of growth. Horm Res. 2002;58(Suppl 1):133–8.

38. Conover CA, Bale LK, Overgaard MT, Johnstone EW, Laursen UH, Füchtbauer EM, et al. Metalloproteinase pregnancy-associated plasma protein-a is a critical growth regulatory factor during fetoplacental development. Development. 2004;131(5):1187–94.

39. Ning Y, Schuller AGP, Conover CA, Pintar JE. Insulin-like growth factor (IGF) binding Protein-4 is both a positive and negative regulator of IGF activity in vivo. Mol Endocrinol. 2008;22(5):1213–25.

40. Chang AC, Hook J, Lernack FT, McDonald MM, Nguyen MA, Hardeman EC, et al. The murine stanniocalcin 2 gene is a negative regulator of postnatal growth. Endocrinology. 2008;149(5):2403–10.

41. Gagliardi AD, Niu YY, Rauh WJ, Wagner GF, DiMattia GE. Human insulin-like growth factor binding protein-4 fragments as markers of cardiovascular mortality in type 1 diabetes patients. Horm Res. 2005;64:322–6.

42. Frost RA, Lang CH. Alteration of somatotropic function by proinflammatory cytokines. J Anim Sci. 2004;82:E-Suppl100–9.

43. Hochberg Z. Mechanisms of steroid impairment of growth. Horm Res. 2002;58(Suppl 1):133–8.

44. Conover CA, Bale LK, Overgaard MT, Johnstone EW, Laursen UH, Füchtbauer EM, et al. Metalloproteinase pregnancy-associated plasma protein-a is a critical growth regulatory factor during fetoplacental development. Development. 2004;131(5):1187–94.

45. Ning Y, Schuller AGP, Conover CA, Pintar JE. Insulin-like growth factor (IGF) binding Protein-4 is both a positive and negative regulator of IGF activity in vivo. Mol Endocrinol. 2008;22(5):1213–25.

46. Chang AC, Hook J, Lernack FT, McDonald MM, Nguyen MA, Hardeman EC, et al. The murine stanniocalcin 2 gene is a negative regulator of postnatal growth. Endocrinology. 2008;149(5):2403–10.

47. Gagliardi AD, Niu YY, Rauh WJ, Wagner GF, DiMattia GE. Human insulin-like growth factor binding protein-4 fragments as markers of cardiovascular mortality in type 1 diabetes patients. Horm Res. 2005;64:322–6.

48. Mason EJ, Grell JA, Wan J, Cohen P, Conover CA. Insulin-like growth factor (IGF)-I and IGF-II contribute differentially to the phenotype of pregnancy-associated plasma protein-a knock-out mice. Growth Hormon IGF Res. 2011;21(5):243–7.

49. Ning Y, Schuller AGP, Bradhaw S, Rotwein P, Ludwig T, Frystyk J, et al. Diminished growth and enhanced glucose metabolism in triple knockout mice containing mutations of insulin-like growth factor binding Protein-3, −4, and −5. Mol Endocrinol. 2006;20(9):2173–86.

50. Gruber HE, Hoelscher GL, Ingram JA, Morton DS, Hanley EN. Human annulus fibrosus maternal origin. J Neurosci Res. 2003;71(5):721–13.
54. Li W, Li H, Gu F. CRP and TNF-induce PAPP-A expression in human peripheral blood mononuclear cells. Mediat Inflamm. 2012;2012:9.
55. Resch ZT, Oxvig C, Bale LK, Conover CA. Stress-activated signaling pathways mediate the stimulation of pregnancy-associated plasma protein-a expression in cultured human fibroblasts. Endocrinology. 2006;147(2):885–90.
56. Hjortebjerg R. IGFBP-4 and PAPP-A in normal physiology and disease. Growth Hormon IGF Res. 2018;41:7–22.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.